Aroa Biosurgery (ASX:ARX) TTM Profitability Emerges While 1H Loss Tests Bullish Growth Narrative

Simply Wall St.

May 27

Aroa Biosurgery (ASX:ARX) has just reported FY 2026 first half revenue of NZ$44.9 million, with a reported loss of NZ$1.3 million and basic EPS of NZ$0.0038 loss, while the trailing twelve months show...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2638650183"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2638650183\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2638650183?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-05-27 18:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638650183","market":"us","top_or_hot":-1,"title":"Aroa Biosurgery (ASX:ARX) TTM Profitability Emerges While 1H Loss Tests Bullish Growth Narrative","media":"Simply Wall St.","content":"<div>\n<p>Aroa Biosurgery (ASX:ARX) has just reported FY 2026 first half revenue of NZ$44.9 million, with a reported loss of NZ$1.3 million and basic EPS of NZ$0.0038 loss, while the trailing twelve months show...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/aroa-biosurgery-asxarx-ttm-profitability-emerges-while-1h-lo\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aroa Biosurgery (ASX:ARX) TTM Profitability Emerges While 1H Loss Tests Bullish Growth Narrative</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAroa Biosurgery (ASX:ARX) TTM Profitability Emerges While 1H Loss Tests Bullish Growth Narrative\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-27 18:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/aroa-biosurgery-asxarx-ttm-profitability-emerges-while-1h-lo><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aroa Biosurgery (ASX:ARX) has just reported FY 2026 first half revenue of NZ$44.9 million, with a reported loss of NZ$1.3 million and basic EPS of NZ$0.0038 loss, while the trailing twelve months show...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/aroa-biosurgery-asxarx-ttm-profitability-emerges-while-1h-lo\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/aroa-biosurgery-asxarx-ttm-profitability-emerges-while-1h-lo","article_id":"2638650183","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-arx/aroa-biosurgery-shares/news/aroa-biosurgery-asxarx-ttm-profitability-emerges-while-1h-lo","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2638650183","pubTimestamp":1779876474,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Aroa Biosurgery (ASX:ARX) has just reported FY 2026 first half revenue of NZ$44.9 million, with a reported loss of NZ$1.3 million and basic EPS of NZ$0.0038 loss, while the trailing twelve months show revenue of NZ$103.9 million and net income of NZ$4.7 million translating to basic EPS of NZ$0.0135. Over recent periods the company has seen revenue move from NZ$39.2 million in 1H FY 2025 to NZ$45.5 million in 2H FY 2025, alongside EPS shifting from NZ$0.0096 loss to NZ$0.0015 loss. Together,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","ARX.AU":"AROA BIOSURGERY LTD"},"translate_title":"Aroa Biosurgery(ASX：ARX)TTM盈利能力显现，而上半年亏损考验看涨增长叙事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARX.AU":1.98},"content_text":"Aroa Biosurgery (ASX:ARX) has just reported FY 2026 first half revenue of NZ$44.9 million, with a reported loss of NZ$1.3 million and basic EPS of NZ$0.0038 loss, while the trailing twelve months show revenue of NZ$103.9 million and net income of NZ$4.7 million translating to basic EPS of NZ$0.0135. Over recent periods the company has seen revenue move from NZ$39.2 million in 1H FY 2025 to NZ$45.5 million in 2H FY 2025, alongside EPS shifting from NZ$0.0096 loss to NZ$0.0015 loss. Together, these figures provide a clearer picture of how margins are now flowing through the P&L and what that could mean for the latest print. See our full analysis for Aroa Biosurgery. With the numbers on the table, the next step is to set these results against the widely held market narratives around Aroa Biosurgery to see which views hold up and which start to look out of date. See what the community is saying about Aroa Biosurgery ASX:ARX Revenue & Expenses Breakdown as at May 2026 AdvertisementTTM profit contrasts with 1H loss  Across the trailing 12 months, Aroa reported net income of NZ$4.7 million and basic EPS of NZ$0.0135, while the latest 1H FY 2026 period on its own still shows a loss of NZ$1.3 million and basic EPS of NZ$0.0038 loss. What stands out for the bullish narrative is that this recent move into profitability in the trailing 12 months sits alongside five year earnings growth of 35.3% per year and forecast earnings growth of about 49.5% per year. However, the most recent half year loss shows that the ramp is not linear and that quarter to quarter swings can still challenge the bullish expectation of a smooth earnings path.\n     Bulls point to the NZ$103.9 million of trailing 12 month revenue and NZ$4.7 million profit as evidence that the business model is now working, while the NZ$44.9 million of 1H FY 2026 revenue and NZ$1.3 million loss highlight that shorter periods can still be lumpy as costs and growth investments hit the income statement. The forecast revenue growth of about 12.5% per year is framed as a key support for the bullish view, but the step from a 1H loss to sustained positive EPS is where the numbers will need to keep lining up for that growth story to stay intact.    Bulls argue that this transition from losses to a NZ$4.7 million trailing profit could be the early phase of a much larger growth story, and that context is unpacked further in the 🐂 Aroa Biosurgery Bull Case High P/E of 62.2x anchors debate  The stock is trading on a trailing P/E of 62.2x compared with a Global Biotechs industry average of 26.2x and a peer average of 4.4x decline, so the shares are priced on a richer multiple than both groups even after the recent shift into profitability. Critics highlight that this elevated 62.2x P/E sits alongside a current share price of A$0.69 and an analyst price target of A$1.07. The bearish narrative therefore focuses less on whether the business can grow and more on whether the current multiple already embeds a lot of that growth, especially given forecasts call for earnings growth of about 49.5% per year and revenue growth of 12.5% per year.\n     Bears argue that if those growth rates or margin gains fall short, the gap between the 62.2x multiple and the 26.2x industry average could make the stock vulnerable to a lower P/E even if revenue continues to increase. At the same time, the bearish view needs to square this concern with the fact that the stock trades below a DCF fair value of A$0.97 and below the A$1.07 analyst target, which suggests not every valuation measure is pointing to the same conclusion.    Skeptics warn that paying a 62.2x P/E for a company that only recently turned profitable leaves little room for disappointment, and that tension is laid out in the 🐻 Aroa Biosurgery Bear Case DCF fair value vs current price  The stock currently trades at A$0.69 against a DCF fair value of A$0.97, so on that measure the price sits about 29.1% below the modelled future cash flow value even as the business has only recently reported a trailing 12 month profit of NZ$4.7 million. Consensus narrative notes that this apparent discount is being weighed against execution risks around U.S. reimbursement changes and surgeon adoption. This means the valuation gap is not just about the earnings numbers on their own but also about how quickly revenue, margins and EPS can move from the recent 1H FY 2026 loss of NZ$1.3 million toward the longer term forecasts.\n     The analyst target of A$1.07 assumes revenue of NZ$144.0 million and earnings of NZ$20.4 million by 2029, much higher than the current trailing 12 month revenue of NZ$103.9 million and profit of NZ$4.7 million, so the market is being asked to weigh a sizeable step up from today’s base. At the same time, the company’s recent shift to profitability in the trailing 12 months shows that some of that journey has already begun, which is why the DCF fair value and price target can both sit above the current A$0.69 share price while the headline P/E still looks expensive.    Next Steps To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Aroa Biosurgery on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves. With sentiment split between optimism and caution, this is a moment to move quickly and test the story against the numbers yourself. To see what those potential upsides look like in detail, review the 3 key rewards See What Else Is Out There Aroa Biosurgery combines a recent trailing profit with a 62.2x P/E and a 1H FY 2026 loss, so execution risks and valuation tension remain clear. If you want ideas where pricing looks tighter against fundamentals and growth expectations, start comparing opportunities with the 9 high quality undervalued stocks  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}